Lamzede

Active Ingredient(s): Velmanase Alfa-tycv
FDA Approved: * February 16, 2023
Pharm Company: * CHIESI FARMACEUTICI SPA
Category: Genetic Disorders
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lamzede 10 mg Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 10122-180
Labeler:
Chiesi USA, Inc.